Articles from Tango Therapeutics, Inc.; Erasca, Inc.
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
The study is evaluating the combination in patients with MTAP-deleted pancreatic cancer and MTAP-deleted/RAS mutant non-small cell lung cancer
By Tango Therapeutics, Inc.; Erasca, Inc. · Via GlobeNewswire · November 4, 2026